Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Vortioxetine hydrobromide

A technology of piperazine hydrobromide and dimethylphenylsulfanyl, used in the treatment of depression, especially the drug of severe depression in adults, the drug of 1-[2-phenyl]piperazine hydrobromide, Inhibitors of the serotonin transporter, the crystalline domain of the drug, can address issues such as SSRI blockage

Active Publication Date: 2014-10-29
BEIJING LABWORLD BIO MEDICINE TECH
View PDF11 Cites 22 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] However, therapeutic use of SSRIs is hampered by the large number of non-responders, ie patients who do not respond or respond to SSRI therapy to a limited extent

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vortioxetine hydrobromide
  • Vortioxetine hydrobromide
  • Vortioxetine hydrobromide

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0240] Embodiment 1: Preparation of the crystallization (B crystal form) of the compound of formula I

[0241] (1) Dissolve 8 g of vortioxetine free base in toluene, add 1 equivalent of hydrobromic acid (48% hydrobromic acid aqueous solution), stir and crystallize, and filter the precipitate to obtain vortioxetine hydrobromic acid Salt (93%);

[0242] (2) Put 10 g of the product obtained in step (1) into a three-necked flask, add 100 g of toluene and 10 g of water, heat to 85 ° C and stir to dissolve, cool and crystallize, and dry the filtered crystals at 60-70 ° C to obtain hydrogen Vortioxetine bromate (90%);

[0243] (3) Put 1 g of the product obtained in step (2) into a three-necked flask, add 12 g of acetone, stir at 55-60° C. for 30 minutes to form a slurry, then stir at room temperature for 1.5 hours, filter, and vacuum-dry the obtained crystals to obtain It is a crystal of the B crystal form.

[0244] The powder X-ray diffraction figure of above-mentioned step (3)...

Embodiment 2

[0245] Embodiment 2: Preparation of the crystallization (B crystal form) of the compound of formula I

[0246] (1) Dissolve 8 g of vortioxetine free base in toluene, add 1.05 equivalents of hydrobromic acid (47% hydrobromic acid aqueous solution), stir and crystallize, and filter the precipitate to obtain vortioxetine hydrobromic acid Salt (91%);

[0247] (2) Put 10 g of the product obtained in step (1) into a three-necked flask, add 80 g of toluene and 8 g of water, heat to 85 ° C and stir to dissolve, cool and crystallize, and dry the filtered crystals at a temperature of 60-70 ° C to obtain hydrogen Vortioxetine bromate (92%);

[0248] (3) Put 1 g of the product obtained in step (2) into a three-necked flask, add 10 g of acetone, stir at 55-60°C for 20 minutes to form a slurry, then stir at room temperature for 1 hour, filter, and vacuum-dry the obtained crystals to obtain It is a crystal of the B crystal form.

[0249] The powder X-ray diffraction figure of above-ment...

Embodiment 3

[0250] Embodiment 3: Preparation of the crystallization (B crystal form) of the compound of formula I

[0251] (1) Dissolve 8 g of vortioxetine free base in toluene, add 0.95 equivalent of hydrobromic acid (47% hydrobromic acid aqueous solution), stir and crystallize, and filter the precipitate to obtain vortioxetine hydrobromic acid Salt (92%);

[0252] (2) Put 10 g of the product obtained in step (1) into a three-necked flask, add 120 g of toluene and 12 g of water, heat to 85 ° C and stir to dissolve, cool and crystallize, and dry the filtered crystals at 60-70 ° C to obtain hydrogen Vortioxetine bromate (91%);

[0253] (3) Put 1 g of the product obtained in step (2) into a three-necked flask, add 15 g of acetone, stir at 55-60° C. for 40 minutes to form a slurry, then stir at room temperature for 2 hours, filter, and vacuum-dry the obtained crystals to obtain It is a crystal of the B crystal form.

[0254] The powder X-ray diffraction figure of above-mentioned step (3...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to vortioxetine hydrobromide and in particular relates to a crystal of 1-[2-(2,4-dimethylphenylthioxo)phenyl] piperazine hydrobromide. The crystal uses Cu-K alpha radiation. In a powder X-ray diffraction pattern shown by a 2theta angle, diffraction peaks exist at about 6.89 degrees, 9.73 degrees, 13.78 degrees and 14.62 degrees. The invention also relates to a preparation method of the crystal and a drug composition containing the compound. The compound shows the serotonin reabsorption inhibitory activity, has activities towards a serotonin receptor 1A (5-HT1A) and a serotonin receptor 3 (5-HT3), can be used for treating CNS (central nervous system)-related diseases, in particular can be used for treating depressive disorder, especially major depressive disorder of adults, and can be also used for treating other CNS-related diseases.

Description

technical field [0001] The present invention relates to a compound which exhibits serotonin reuptake inhibitory activity, and which exhibits serotonin receptor 1A (5-HT 1A ) and serotonin receptor 3 (5-HT 3 ) has activity, and the compound can be used to treat CNS-related diseases. More specifically, the present invention relates to an inhibitor of 5-hydroxytryptamine transporter, which is a drug that can be used to treat depression, especially major depression in adults, and especially relates to a chemical name that can be called 1-[2 -(2,4-Dimethylphenylsulfanyl)phenyl]piperazine hydrobromide, more particularly to the crystallization of said drug. The 1-[2-(2,4-dimethylphenylthio)phenyl]piperazine hydrobromide has the following chemical structure: [0002] Background technique [0003] Selective serotonin reuptake inhibitors (SSRIs) have been the first-choice therapy for many years for the treatment of certain CNS-related disorders, notably depression, anxiety, and ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D295/096A61K31/495A61K47/26A61P25/00A61P25/24A61P25/28A61P25/18A61P35/00A61P25/16A61P25/22A61P29/00A61P25/30
CPCC07D295/096
Inventor 温光辉解卓峰付冀峰宛六一
Owner BEIJING LABWORLD BIO MEDICINE TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com